Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial

Autor: Eron, Joseph J, Jr, Lelievre, Jean-Daniel, Kalayjian, Robert, Slim, Jihad, Wurapa, Anson K, Stephens, Jeffrey L, McDonald, Cheryl, Cua, Eric, Wilkin, Aimee, Schmied, Brigitte, McKellar, Mehri, Cox, Stephanie, Majeed, Sophia R, Jiang, Shuping, Cheng, Andrew, Das, Moupali, SenGupta, Devi

Publikováno v: In The Lancet HIV January 2019 6(1):e15-e24

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

High rates of virologic suppression with DTG/3TC in newly diagnosed adults with HIV-1 infection and baseline viral load >500,000 c/mL: 48-week subgroup analysis of the STAT study.

Autor: Rolle, Charlotte-Paige, Berhe, Mezgebe, Singh, Tulika, Ortiz, Roberto, Wurapa, Anson, Ramgopal, Moti, Jayaweera, Dushyantha T., Leone, Peter A., Matthews, Jessica E., Cupo, Michael, Underwood, Mark R., Angelis, Konstantinos, Wynne, Brian R., Merrill, Deanna, Nguyen, Christopher, van Wyk, Jean, Sang-Kyu Shin, Zolopa, Andrew R.

Publikováno v: Infection & Chemotherapy; 2022 Supplement, Vol. 54, pS295-S297, 3p

Oral Hairy Leukoplakia: A Manifestation of Primary Infection with Epstein-Barr Virus?

Autor: Wurapa, Anson K.¹, Luque, Amneris E., Menegus, Marilyn A.

Publikováno v: Scandinavian Journal of Infectious Diseases. Oct1999, Vol. 31 Issue 5, p505-506. 2p. 1 Black and White Photograph.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

Autor: Eron JJ Jr; Department of Medicine, Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA., Lelievre JD; Department of Clinical Immunology & Infectious Diseases, Hôpital Henri Mondor, Créteil, France., Kalayjian R; Infectious Diseases, MetroHealth, Cleveland, OH, USA., Slim J; Infectious Diseases, Saint Michael's Medical Center, Newark, NJ, USA., Wurapa AK; Infectious Disease Specialists of Atlanta PC, Decatur, GA, USA., Stephens JL; Department of Internal Medicine, Mercer University School of Medicine, Macon, GA, USA., McDonald C; Tarrant County Infectious Disease Associates, Fort Worth, TX, USA., Cua E; Department of Infectious Diseases, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France., Wilkin A; Section on Infectious Disease, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Schmied B; Sozialmedizinisches Zentrum Baumgartner Höhe Otto-Wagner Hospital, Vienna, Austria., McKellar M; Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, NC, USA., Cox S; Department of Virology, Gilead Sciences, Foster City, CA, USA., Majeed SR; Department of Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA., Jiang S; Department of Biometrics, Gilead Sciences, Foster City, CA, USA., Cheng A; Department of HIV Clinical Research, Gilead Sciences, Foster City, CA, USA., Das M; Department of HIV Clinical Research, Gilead Sciences, Foster City, CA, USA., SenGupta D; Department of HIV Clinical Research, Gilead Sciences, Foster City, CA, USA. Electronic address: Devi.SenGupta@gilead.com.

Publikováno v: The lancet. HIV [Lancet HIV] 2018 Dec 13. Date of Electronic Publication: 2018 Dec 13.